Xilio Therapeutics Grants Equity Compensation to New Employees Under Nasdaq Listing Rules

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)

April 4, 2025 - South San Francisco, CA - Xilio Therapeutics, a biotechnology company focused on developing novel, best-in-class therapies for patients with severe and debilitating diseases, today announced that it has granted equity awards to certain new and continuing employees under its equity incentive plan.

The inducement grants were made under Nasdaq Listing Rule 5635(c) and were approved by the Compensation Committee of the Board of Directors of Xilio Therapeutics. The equity awards consist of options to purchase shares of Xilio Therapeutics' common stock, with a grant date of April 4, 2025. The number of shares subject to each option and the exercise price per share are as follows:

• 100,000 options to purchase shares of common stock with an exercise price of $2.50 per share
• 50,000 options to purchase shares of common stock with an exercise price of $2.50 per share
• 25,000 options to purchase shares of common stock with an exercise price of $2.50 per share

The options will vest over a period of four years, with 25% of the shares subject to each option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in equal quarterly installments over the next three years. The options will expire ten years from the grant date.

The equity awards were made to the following individuals:

• [Name], as a new employee of Xilio Therapeutics, in connection with his employment with the company
• [Name], as a new employee of Xilio Therapeutics, in connection with his employment with the company
• [Name], as a continuing employee of Xilio Therapeutics, in connection with his continued employment with the company

Xilio Therapeutics is a biotechnology company focused on developing novel, best-in-class therapies for patients with severe and debilitating diseases. The company's lead program is focused on developing a novel, orally available, small molecule therapy for the treatment of inflammatory bowel disease (IBD). Xilio Therapeutics is headquartered in South San Francisco, California.